Drugs / GS-2121
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06532565 | Jul 2024 → Jun 2028 expected | cancer | Gilead Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-2121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532565 ↗ |
| Route | Oral | “Tablet administered orally” NCT06532565 ↗ |